Publications

1. Clinical Studies:

1.1 Stem Cell Educator therapy in type 1 diabetes

• Yong Zhao*, Zhaoshun Jiang,  Tingbao Zhao, et al. Reversal of Type 1 Diabetes via Islet beta Cell Regeneration Following Immune Modulation by Cord Blood-Derived Multipotent Stem Cells. BMC Medicine. 2012 Jan 10; 10(1): 3.

 1.2 Stem Cell Educator therapy in type 2 diabetes

• Yong Zhao*, Zhaoshun Jiang,  Mingliang Ye, et al. Targeting insulin resistance via the immune modulation of cord blood-derived multipotent stem cells by the Stem Cell Educator Therapy. Diabetes. 61: S1, A-75, 2012.

 1.3 Invited Review articles:

• Yong Zhao*. Stem Cell Educator Therapy and Induction of Immune Balance. Current Diabetes Reports. 12: online 2012.
• Yong Zhao*, Zhaoshun Jiang, Chengshan Guo. New hope for type 2 diabetics: targeting insulin resistance through the immune modulation of stem cells. Autoimmunity Reviews. 11: 137-142, 2011
• Yong Zhao*, Theodore Mazzone. Human cord blood stem cells and the journey to a cure for type 1 diabetes. Autoimmunity Reviews. 10:103-107, 2010.

2. Pre-clinical Studies in Humans: 

2.1 Identification of human cord blood-derived multipotent stem cells (CB-SCs)

• Yong Zhao*, Honglan Wang, Theodore Mazzone. Identification of pluripotent stem cells from umbilical cord blood with embryonic and hematopoietic characteristics. Experimental Cell Research. 312: 2454-2464, 2006.

 2.2 First demonstrate that CB-SCs display immune modulation.

• Yong Zhao*, Zhihua Huang, Meirigeng Qi, Ping Lazzarini, Theodore Mazzone. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunology Letters.108:78-87, 2007.

 2.3 Differentiation of CB-SCs into dopamine neurons.

• Xiaohong Li, Heng Li, Jianfen Bi, Yana Chen, Sumit Jain, Yong Zhao*. Human cord blood-derived multipotent stem cells (CB-SCs) treated with all-trans-retinoic acid (ATRA) give rise to dopamine neurons. Biochem Biophys Res Commun. 419(1):110-6, 2012.

 2.4 Identification of peripheral blood-derived insulin-producing cells (PB-IPC).

• Y Zhao*, Z Huang, P Lazzarini, Y Wang, A Di and M Chen. A unique human blood-derived cell population displays high potential for producing insulin. Biochem Biophys Res Commun. 360: 205-211, 2007.

3. Pre-clinical Studies in Mice:

3.1 Demonstrate the reversal of type 1 diabetes by the immune modulation of CB-SCs in mice.

• Yong Zhao*, Brian Lin, Robert Darflinger, Yongkang Zhang, Mark Holterman, Randal A. Skidgel. Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. Plos ONE. 4 (1): e4226, 2009.
• Yong Zhao*, Brian Lin, Michael Dingeldein, Chengshan Guo, David Hwang, Mark J. Holterman. The new type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes. Translational Research (Previous name: The Journal of Laboratory and Clinical Medicine). 155: 211-16, 2010.

 3.2 Establishment of humanized immune-caused type 1 diabetic mouse model.

• Yong Zhao*, Chengshan Guo, David Hwang, Brian Lin, Michael Dingeldein, Dan Mihailescu, Susan Sam, Seema Sidhwani, Yongkang Zhang, Sumit Jain, Randal A. Skidgel, Bellur S. Prabhakar, Theodore Mazzone, Mark J. Holterman. Selective Destruction of Mouse Islet Beta Cells by Human T Lymphocytes in a Newly-Established Humanized Type 1 Diabetic Model. Biochem Biophys Res Commun. 399: 629-636, 2010.